Introduction {#s1}
============

Cervical cancer, the third most common cancer in women [@pone.0086061-Jemal1], is mainly caused by human papillomavirus (HPV) infection [@pone.0086061-Walboomers1]. Although HPV infections are prevalent in sexually active women, only a minority of infections persist and develop into cervical intraepithelial neoplasia grade 2/3 (CIN 2/3) or even cervical cancer [@pone.0086061-McCredie1]. Several cofactors affect the transition from initial HPV infection to cervical cancer, including life-style, host immune response, and genetic susceptibility [@pone.0086061-Wang1], [@pone.0086061-Wang2]. The important roles of genetic factors in cervical cancer pathogenesis are prompted by the findings that cervical cancer exhibits a significant familial clustering and the first degree relatives of patients have double risk of developing cancer [@pone.0086061-Magnusson1]. A few risk-modulating variants for cervical cancer have been identified by a candidate gene association study. The genes that are associated with cervical cancer susceptibility are involved in DNA repair, cellular cycle and apoptosis, cell proliferation and differentiation, the human leukocyte antigen system and immune responses [@pone.0086061-Safaeian1], [@pone.0086061-Ferguson1].

Recent compelling evidence indicates that polymorphisms in microRNA (miRNA) binding sites of cancer-related genes are an important source that harbors the causative genetic variants of cancer [@pone.0086061-Ryan1]. miRNA, often 19--25 nucleotide-length noncoding RNA, binds within the 3′ untranslated region (UTR) of transcriptions of targeted genes to inhibit and even abolish its translation to protein. It is estimated that approximately 30% of human genes are regulated by miRNAs [@pone.0086061-Carthew1]. Gene deregulation is one of the key mechanisms by which cells can progress to cancer [@pone.0086061-Compagni1]. miRNA can participate in the carcinogenesis via post-transcriptional regulation of many cancer-related genes, including oncogenes and tumor suppressor genes. The aberrant expression of miRNAs contributes to the etiology of multiple cancers, including cervical cancer [@pone.0086061-Deftereos1]. miRNA profile analysis of cervical cancer revealed that miRs-9, 21, 135b, 146a, 199a, 203 and 205 are frequently overexpressed in cancer tissues or cell lines [@pone.0086061-Deftereos1]. Moreover, miR-205 acts as an oncogene to promote cell proliferation and migration of human cervical cancer cells [@pone.0086061-Xie1]. In contrast, miR-214 directly targets the GALNT7 gene to suppress growth and invasiveness of cervical cancer cells by functioning as a tumor suppressor a tumor suppressor [@pone.0086061-Peng1]. The base pair change within the miRNA-target region of cancer-related genes could destroy or create a binding site or alter the binding affinity and post-transcriptional control of mRNA by miRNA and, therefore, could affect the transformation from normal cells to cancer cells [@pone.0086061-Ryan1].

Bioinformatics analysis has identified many SNPs that are located in the putative miRNA binding sites of cancer candidate genes and that significantly affect the binding energy of putative miRNA::mRNA duplexes [@pone.0086061-Ziebarth1]. A small fraction of them have been further proved to alter the expression of target genes by the luciferase reporter assay and display a significant association with susceptibility to cancer [@pone.0086061-Landi1], [@pone.0086061-Naccarati1]. Landi et al. screened out 57 SNPs within miRNA-binding sites from 104 candidate genes for colorectal cancer, found eight SNPs of them showing various Gibbs free energy of binding between the two alleles of each SNP, and finally demonstrated a SNP, rs17281995, within the miRNA-binding sites of CD86, as the risk-modulating variant for colorectal cancer [@pone.0086061-Landi1]. Using a similar research strategy, SNPs within miRNA binding sites of other important cancer candidate genes, such as DNA repair genes [@pone.0086061-Naccarati1], integrin genes [@pone.0086061-Brendle1] and caspase genes [@pone.0086061-Guan1], have also been identified and further evaluated as susceptibility variants for bladder cancer, breast cancer, colorectal cancer, and head and neck cancer risk. Recently, Shi et al. demonstrated that the rs11064 G allele within the *TNFAIP8* gene weakens the binding affinity of miR-22 to the TNFAIP8 3′- UTR and is associated with an increased risk of cervical cancer [@pone.0086061-Shi1], which suggests that miRNA-binding sites are also the hot spots that harbor cervical cancer susceptibility variants.

In the present study, we sought to identify new risk variants for cervical cancer among miRNA-target sites in cancer-related genes. By reviewing the literature and bioinformatics databases, we found 37 cancer-related genes with variations in putative 3′-UTR miRNA binding sites. The association strength of these variants with cervical cancer was assessed by a two-stage case-control study. For the associated variant, its functional influence on miRNA-mediated expression regulation of the target genes was investigated using the luciferase reporter assay.

Materials and Methods {#s2}
=====================

1 Study population {#s2a}
------------------

We recruited 840 patients with cervical cancer from the patients who received inpatient treatment in three hospitals between May 2008 and April 2012. Among them, 338 subjects from Liaocheng People\'s Hospital (LCPH) were used in first stage study (Study 1), which investigated all of the selected SNPs, and 502 subjects from The First Affiliated Hospital of Xi\'an Jiaotong University (TFAHXJTU) and Maternal and Child Health Hospital of Shaanxi Province (MCHHSP) were used in second stage study (Study 2), which was to replicate the noteworthy findings (*P*\<0.05) from Study 1. All of the patients were diagnosed by histological examination of biopsy under colposcope and/or resected tissues. The clinical stage and histological type of cervical cancer of patients were collected from medical records and are shown in [Table 1](#pone-0086061-t001){ref-type="table"}. A total of 934 healthy controls were recruited from the women who routinely attended physical examination in these three hospitals, 334 subjects from LCPH in Study 1 and 600 subjects from TFAHXJTU and MCHHSP in Study 2. All of the controls had no history of neoplastic or cancer-associated illness, and they had normal cervical cytology in at least two consecutive annual examinations. All of the subjects were genetically unrelated, and their age, race, smoking status, socio-economic status, and marital status were also investigated by reading medical records or by interviews. This study was approved by the Medical Ethics Committees of LCPH, TFAHXJTU, and MCHHSP and all of the participants gave informed written consent.

10.1371/journal.pone.0086061.t001

###### The characteristics of patients with cervical cancer and cancer-free controls.

![](pone.0086061.t001){#pone-0086061-t001-1}

                                                                        Study 1                                 Study 2                                   All        subjects   
  ------------------------------------------------------------------- ------------ ------------ ------------- ------------ ------------ ------------- ------------ ------------ -------------
  **Age** [a](#nt101){ref-type="table-fn"} **, year (Mean**±**SD)**    47.2±10.8     46.5±8.7       0.355      48.4±11.2     47.5±9.5       0.262      48.0±11.1     47.1±9.2       0.065
  **Race, n (%)**                                                                                                                                                               
  Han Chinese                                                          290 (86.8)   285 (84.3)      0.355      538 (89.7)   453 (90.2)      0.753      828 (88.7)   738 (87.9)      0.604
  Hui Chinese                                                          44 (13.2)    53 (15.7)                  62 (10.3)     49 (9.8)                  106 (11.3)   102 (12.1)  
  **Smoking**                                                                                                                                                                   
  Never                                                                305 (91.3)   313 (92.6)      0.540      562 (93.7)   448 (89.2)      0.008      867 (92.8)   761 (90.6)      0.088
  Ever                                                                  29 (8.7)     25 (7.4)                   38 (6.3)    54 (10.8)                   67 (7.2)     79 (9.4)   
  **Education**                                                                                                                                                                 
  JHS and below                                                        189 (56.6)   201 (59.5)      0.550      314 (52.3)   282 (56.2)      0.717      503 (53.9)   483 (57.5)      0.488
  SHS and above                                                        145 (43.4)   137 (40.5)                 286 (47.7)   220 (43.8)                 431 (46.1)   357 (42.5)  
  **Age at primiparity**                                                                                                                                                        
  ≤24 years                                                            206 (63.6)   219 (66.6)      0.424      390 (67.0)   365 (73.1)      0.031      596 (65.8)   575 (70.5)      0.038
  \>24 years                                                           118 (36.4)   110 (33.4)                 192 (33.0)   131 (26.9)                 310 (34.2)   241 (29.5)  
  Missing or nulliparous                                                   10           9                          18           15                         28           24      
  **Marital status**                                                                                                                                                            
  Never married                                                         6 (1.9)      4 (1.2)        0.195       15 (2.7)     11 (2.3)       0.145       21(2.4)      15 (1.8)       0.035
  Married only once                                                    259 (83.5)   264 (79.3)                 453 (80.3)   370 (76.0)                 712 (81.5)   634 (77.4)  
  ≥2 times                                                             45 (14.5)    65 (19.5)                  96 (17.0)    106 (21.7)                 141 (16.1)   171 (20.9)  
  Missing                                                                  24           5                          36           15                         60           20      
  **HPV infection status**                                                                                                                                                      
  HPV +                                                                106 (31.7)   296 (87.6)   **\<0.001**   229 (38.2)   420 (83.7)   **\<0.001**   335 (35.9)   716 (85.2)   **\<0.001**
  HPV -                                                                228 (68.3)   42 (12.4)                  371 (61.8)   82 (16.3)                  599 (64.1)   124 (14.8)  
  **Clinical stage** [c](#nt103){ref-type="table-fn"}                                                                                                                           
  I                                                                                 247 (73.1)                              365 (72.7)                              612 (72.9)  
  II                                                                                69 (20.4)                               118 (23.5)                              187 (22.3)  
  II I/IV                                                                            22 (6.5)                                19 (3.8)                                41 (4.9)   
  **Histology**                                                                                                                                                                 
  SC                                                                                280 (82.8)                              398 (79.3)                              678 (80.7)  
  Adenocarcinoma                                                                     44 (13)                                75 (14.9)                               119 (14.2)  
  Other                                                                              14 (4.1)                                29 (5.8)                                43 (5.1)   

Age of diagnosis for cases and age when they participated in this study for controls.

Statistically significant results with an FPRP value \<0.2 are marked in bold.

Based on International Federation of Gynecology and Obstetrics classification system.

Abbreviation: SD, standard deviation; JHS, junior high school; SHS, senior high school; SC: Squamous carcinoma.

2 Polymorphism selection and genotyping {#s2b}
---------------------------------------

Previous studies have systematically screened the SNPs in miRNA binding sites of many cancer-related genes. Briefly, they first screened cancer-related genes by database and literature searches, and then, they identified the putative miRNA target sites in these genes by specialized algorithms (such as miRBase, miRanda, PicTar and TargetScan) and selected the SNPs that reside on the miRNA-binding sites by dbSNP search and BLAST, finally identifying the SNPs whose alleles make the target sequence have significantly differential binding energy to miRNA in a computer predictive model [@pone.0086061-Landi1], [@pone.0086061-Brendle1]. Because many cancer-related genes are shared by multiple cancers [@pone.0086061-Lu1], we selected the SNPs from the previous literature that covers the topics about miRNA-binding site/miRNA target sites, polymorphisms and cancer/tumor. The MedLine/PubMed database was searched to find literature that was published from 2000 January to 2013 January. We lastly selected 41 SNPs in predicted miRNA-binding sites within 37 cancer-related genes with minor allele frequencies greater than 0.1 in the Chinese Han population ([Table 2](#pone-0086061-t002){ref-type="table"}). Genomic DNA was extracted from peripheral blood leukocytes using the Blood DNA Midi Kit (Omega Biotech, Norcross, USA), according to the manufacturer\'s protocol. The selected SNPs were genotyped in patients and controls using MALDI-TOF within the MassARRAY system (Sequenom Inc., San Diego, CA, USA) [@pone.0086061-Jurinke1].

10.1371/journal.pone.0086061.t002

###### The candidate cancer-related genes, the selected SNPs, the miRNAs whose binding to target mRNAs could be altered by the corresponding base substitution, and the frequency distributions of selected SNPs in the cases and controls in Study 1.

![](pone.0086061.t002){#pone-0086061-t002-2}

  Gene                     Function involved                   dbSNP ID      Chromosome/Position   The binding miRNA[a](#nt105){ref-type="table-fn"}   Homozygous major allele (controls/cases)   Heterozygote (controls/cases)   Homozygous major allele(controls/cases)   Chi-squarevalue   *P* value[b](#nt106){ref-type="table-fn"}
  ---------- --------------------------------------------- ---------------- --------------------- --------------------------------------------------- ------------------------------------------ ------------------------------- ----------------------------------------- ----------------- -------------------------------------------
  REV3L                DNA metabolism and repair             rs465646 A/G        6/111620758                          **miR-25**                                       225/253                                98/80                                10/3                          7.216                        **0.027**
  RYR3              Regulation of cytosolic calcium         rs1044129 A/G        15/34158266                          **miR-367**                                      116/110                               173/188                               44/39                         1.06                           0.589
  BIRC5                 Regulation of apoptosis             rs2239680 T/C        17/76219783                          **miR-335**                                      206/183                               116/127                               10/25                         8.27                         **0.016**
  NBS1                        DNA repair                    rs2735383 G/C        8/90947269                           **miR-629**                                      109/115                               150/162                               74/60                         2.061                          0.357
  RAP1A                        Oncogene                       rs6573 C/A         1/112255389                         **miR-196a**                                      196/205                               118/113                               18/20                         0.362                          0.835
  FGF2          Mitosis, angiogenesis and tumor growth      rs1476215 T/A        4/123818271                           miR-196a                                        277/259                                50/56                                5/23                         12.463                        **0.002**
  TGFA          Cell proliferation and differentiation       rs473698 G/C        2/70411736                             miR-495                                        165/165                               130/141                               39/32                         1.113                          0.573
  DGCR8                  microRNAs biogenesis                 rs3757 G/A         22/20099331                            miR-523                                        222/230                               100/99                                10/9                          0.146                          0.93
  ITGA6       Cell proliferation, migration and survival     rs17664 G/A         2/173369231                            miR-152                                        195/213                               112/108                               27/16                         3.667                          0.16
  ITGB3       Cell proliferation, migration and survival    rs3809865 A/T        17/45388586                            miR-26b                                        201/213                               110/115                               23/10                         5.557                          0.062
  ITGB5       Cell proliferation, migration and survival      rs2675 A/C         3/124482113                            miR-504                                        233/246                                94/83                                 5/7                          1.346                          0.51
  LIG3                        DNA Repair                     rs4796030A/C        17/33330150                            miR-612                                        123/127                               156/172                               55/39                         3.544                          0.17
  BRCA1                       DNA Repair                     rs12516 C/T         17/41196408                            miR-874                                        159/153                               133/153                               42/32                         2.842                          0.242
  BRCA1                       DNA Repair                    rs8176318 C/T        17/41197274                            miR-328                                        138/162                               151/142                               45/34                         3.704                          0.157
  XPC                         DNA repair                    rs2229090 C/G        3/14187345                           miR-1225-3p                                      167/173                               135/134                               32/31                         0.102                          0.95
  RPA1                        DNA repair                    rs9914073 A/G        17/1801592                           miR-548c-3p                                      135/147                               157/158                               42/33                         1.57                           0.456
  RPA2                        DNA repair                      rs7356 A/G         1/28218100                            miR-3149                                         87/96                                178/170                               68/72                         0.704                          0.703
  GTF2H1                      DNA repair                      rs4596 G/C         11/18388128                          miR-518a-5p                                       101/88                               180/191                               53/59                         1.518                          0.468
  ERCC4                       DNA Repair                    rs4781563 G/A        16/14045399                          miR-2355-3p                                      195/206                               122/108                               17/21                         1.573                          0.455
  CASP3                        Apoptosis                    rs1049216 C/T        4/185550089                            miR-181                                        187/193                               131/131                               16/14                         0.204                          0.903
  CASP6                        Apoptosis                    rs1042891 C/T        4/110610086                            miR-944                                         96/105                               155/151                               83/82                         0.438                          0.804
  CASP7                        Apoptosis                    rs1127687 G/A       10/115490109                            miR-136                                        191/189                               120/125                               23/24                         0.11                           0.946
  CASP7                        Apoptosis                    rs10787498 T/G      10/115489650                            miR-19a                                        163/179                               149/144                               20/15                         1.495                          0.474
  CASP7                        Apoptosis                    rs12247479 G/A      10/115490060                            miR-345                                        258/271                                69/61                                 7/6                          0.865                          0.649
  CASP7                        Apoptosis                    rs4353229 T/C       10/115489589                            miR-224                                        113/111                               175/183                               46/44                         0.217                          0.897
  E2F1             Cell proliferation and apoptosis         rs3213180 G/C        20/32263624                           miR-1182                                        178/154                               128/135                               26/49                         8.922                        **0.012**
  IL16               Immune response/inflammation           rs1131445 T/C        15/81601782                           miR-135a                                        126/100                               169/180                               39/58                         7.036                        **0.030**
  PTGER4             Immune response/inflammation           rs16870224 G/A       5/40692940                             miR-9,                                         243/234                                83/86                                7/17                          4.366                          0.113
  NOD2               Immune response/inflammation           rs3135500 G/A        16/50766886                            miR-158                                        164/178                               129/132                               41/28                         3.033                          0.219
  PLA2G2A               Phospholipid metabolism               rs11677C/T         1/20301964                             miR-187                                        213/196                               109/121                               12/20                         3.319                          0.19
  ALOX15               Linoleic acid metabolism              rs916055 T/T        17/4138208                             miR-588                                        130/122                               155/151                               49/65                         2.528                          0.283
  IL-23 R            Immune response/inflammation           rs10889677 A/C       1/67725120                           **Let-7e**                                       189/180                               131/141                               14/17                         0.854                          0.653
  TNFAIP2                      Apoptosis                      rs8126 T/C        14/103603569                          **miR-184**                                      144/147                               138/158                               52/33                         5.606                          0.061
  MTMR3                        Apoptosis                     rs12537 C/T         22/30423460                         **miR-181a**                                      224/233                                94/93                                16/12                         0.73                           0.694
  HOXB5       Cellular morphogenesis and differentiation      rs9299 A/G         17/46669430                           **miR-7**                                        92/101                               174/188                               68/49                         4.023                          0.134
  TYMS                DNA replication and repair             rs699517 T/C         18/673016                             miR-498                                        163/155                               130/153                               41/30                         3.751                          0.153
  EFNA1            Tumor development and maintenance         rs12904 A/G         1/155106697                        **miR-200c-3p**                                    210/218                               115/106                               9/14                          1.579                          0.454
  MYCL1               A highly plausible oncogene           rs3134615 C/T        1/40362066                          **miR-1827**                                      271/283                                57/52                                 6/3                          1.466                          0.481
  TGFBR1      Cell proliferation, migration and apoptosis    rs334348 A/G        9/101912471                        **miR-628-5p**                                      104/91                               152/143                              78/104                         4.832                          0.089
  TP53BP2                      Apoptosis                     rs17739 C/T         1/223967953                          miR-129-5p                                       182/161                               127/147                               25/30                         3.176                          0.204
  TP53INP1                A tumor suppressor                  rs7760 T/G         8/95938422                           miR-330-5p                                       241/254                                81/74                                12/10                         0.816                          0.665

The binding miRNAs that are supported by functional experiment, such as the luciferase reporter assay, are in boldface.

*P* value was calculated using a χ^2^ test with 2 d.f. P≤0.05 are in boldface.

3 HPV genotyping {#s2c}
----------------

Human HPV from cervical scraping smear and/or resected tissues was genotyped using the HPV GenoArray test kit (HybriBio Ltd, Guangdong, China). First, HPV DNA was amplified with the L1 consensus HPV primers MY09/MY11 and HMB01. Then, the PCR product processed flow-through hybridization in the manner of a macroarray format with a nylon membrane onto which HPV genotype-specific oligonucleotide probes were immobilized. This technique can identify 21 HPV genotypes, including 5 low-risk types (6, 11, 42, 43, and 44), 14 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), and 2 intermediate-risk types (CP8304 and 53).

4 Serum IL-16 levels {#s2d}
--------------------

The patients\' and controls\' blood samples were collected between 8 and 10 a.m. The sera were centrifuged at 3000 rpm for 10 min and frozen at −80°C. Serum IL-16 levels were measured by commercially available enzyme-linked immunosorbent assay (ELISA) kits (PIERCE Endogen) according to the manufacturer\'s instructions. The minimum level of detection for IL-16 was 0.10 pg/ml. No cross-detection of other cytokines was observed. The intra-assay variation was \<10%.

5 Cell culture {#s2e}
--------------

Human cervical cancer cell lines, HeLa [@pone.0086061-Scherer1] and SiHa [@pone.0086061-Friedl1], were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). These cells were cultured in Dulbecco modified Eagle medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% fetal bovine serum and were grown at 37°C in a humidified 5% carbon dioxide incubator.

6 Transient transfections and luciferase assays {#s2f}
-----------------------------------------------

The 3′-UTR of IL-6 mRNA, including the C allele or T allele of rs1131445, were amplified using the primers of 5′-TGGCCTGGGCCTCCTCACAA-3′ (forward) and 5′- CTCCACCACCCTTCCCTA -3′ (reverse). The amplified fragments were then cloned into the downstream of the firefly luciferase gene in the pGL3-basic vector (Promega, Madison, USA). These recombination plasmids were sequenced to confirm their accuracy. For the luciferase reporter assays, HeLa and SiHa was plated in 24-well dishes to be co-transfected with 100 ng of pGL3-C or pGL3-T constructs, 50 pmol/µL of chemically synthesized miRNAs miR-135b (GenePharma, Shanghai, China) or negative control miRNA using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, USA). In each transfection, 20 ng of pRL-TK plasmid (Promega, Madison, USA) was used to correct for transfection efficiency. Each transfection was conducted in triplicate. Cells were collected 48 hours after transfection, and luciferase activity was measured with a dual-Luciferase reporter assay system (Promega, Madison, USA) and normalized against the activity of the Renilla luciferase gene.

7. Statistical analysis {#s2g}
-----------------------

We calculated the statistical power as previously described [@pone.0086061-Dupont1]. A χ^2^ test was performed to make a comparison of the categorical variables, including the genotype frequency and some demographic characteristics. Student\'s t-test, Mann--Whitney U-test or analysis of variance were conducted to compare the continuous variables, such as the age, serum IL-16 level and reporter expression level, when appropriate. The associations between the *IL-16* variants and the cervical cancer risk were estimated by computing the ORs and their 95% CIs from multivariate logistic regression analyses with an adjustment for the age, body mass index, smoking status and family history of cancer. To avoid a spurious association caused by multiple tests, the false positive report probability (FPRP) was calculated according to the method described by Wacholder et al. [@pone.0086061-Wacholder1]. We set 0.2 as an FPRP threshold and assigned a prior probability of 0.01 to detect an OR of 1.50 (for the risk effects) or 0.67 (for the protective effects) for an association with the SNPs or clinico-demographic features. The Hardy--Weinberg equilibrium (HWE) of the SNPs among the controls was evaluated by the χ^2^ test. All of the statistical analyses were performed by SPSS (version 13.0, Chicago, IL, USA). A value of *P*\<0.05 was considered to be significant (two-tailed).

Results {#s3}
=======

1 Population characteristics {#s3a}
----------------------------

We analyzed altogether 840 patients with cervical cancer and 934 controls in Studies 1 and 2. The demographic and clinical characteristics of patients and controls are presented in [Table 1](#pone-0086061-t001){ref-type="table"}. There was no significant difference in the distribution of the age, race, smoking status, educational level, and marital status between the controls and the cases in Study 1, Study 2 and all of the subjects combined. However, the cases were more likely to be younger at age at first delivery (*P* = 0.038) and with HPV infection (*P*\<0.001) than the controls. HPV infection still remained significantly associated with cervical cancer after considering the FPRP that was less than 0.2. These two variables were further adjusted for any residual confounding effect in later multivariate logistic regression analyses.

2 Association of SNPs within miRNA-binding sites of cancer-related genes with cervical cancer risk {#s3b}
--------------------------------------------------------------------------------------------------

More than 99% of the samples were genotyped successfully for each SNP, and the replicate experiment for the randomly selected 300 samples acquired completely consistent genotype data with the original analysis. [Table 2](#pone-0086061-t002){ref-type="table"} shows the list of selected SNPs within the miRNA-binding sites in the 3′-UTR of 37 cancer-related genes, the binding miRNA that they potentially affect, and their genotype frequencies and associations with cervical cancer in Study 1. All of the observed genotype distributions among the controls of Study 1 were in line with the HWE. Among the 41 SNPs that were included in Study 1, five SNPs (rs465646 in *REV3L* gene, rs2239680 in *BIRC5* gene, rs1476215 in *FGF2* gene, rs3213180 in *E2F1* gene, rs1131445 in *IL-16* gene) exhibited a markedly different genotype distribution between the cases with cervical cancer and the controls (*P* = 0.003∼0.030). To determine whether true significant associations existed or whether there were spurious results, we performed a replicate to analyze these SNPs in another population that resides in Shaan Xi province of Northern China. In Study 2, their observed genotype frequencies were also consistent with HWE ([Table 3](#pone-0086061-t003){ref-type="table"}). Moreover, we found that only *IL-16* rs1131445 continued to show a significant association with cervical cancer. The subjects with its TC or CC allele had an increased risk for cervical cancer (adjusted OR = 1.51, 95% CI 1.18--1.93, *P* = 0.001) with an adjustment for age, smoking status, educational level, age at primiparity, marital status, and HPV infection status. The association between rs1131445 and cervical cancer was more significant in data that combined Study 1 and 2 (adjusted OR = 1.49, 95% CI 1.22--1.81, *P* = 0.00007) with adjustment for the aforementioned variables. We then calculated the FPRP values for all of the observed significant associations. When the assumption of prior probability was 0.01, the association with the *IL-16* rs1131445 (TC/CC vs.TT) was still noteworthy in both Study 1 subjects (FPRP = 0.171) and all subjects (FPRP = 0.011). Given an OR of 1.5 at a nominal *P* = 0.05 for genotype frequencies ranging from 0.20 to 0.40, the statistical power of our study to detect an association of each SNP with cervical cancer in Study 2 and combined Study 1and 2 was estimated at 81.0--91.5% and 95.0--98.9%, respectively. The stratification analysis did not reveal a significant interaction of the demographic and clinical characteristics and the rs1131445 genotype on the cervical cancer risk (data not shown). Additionally, there were not significant correlations between the genotypes of rs1131445 and the clinical stage and histological type of cervical cancer (data not shown).

10.1371/journal.pone.0086061.t003

###### Association of the selected SNPs from the Study 1 and an additional SNP in *IL-16* with the risk for cervical cancer in the Study 2.

![](pone.0086061.t003){#pone-0086061-t003-3}

                                                 Study 2                                                  Combined Study 1and 2                                       
  ----------- ------- ------------ ------------ --------- ------------------ ----------- -- ------------ ----------------------- --------- -------------------------- -------------
  REV3L         AA     432 (72.0)   353 (70.6)    0.741    1.00 (referent)                   657 (70.4)        606 (72.5)          0.599        1.00 (referent)       
  rs465646      AG     153 (25.5)   131 (26.2)             1.05 (0.8∼1.38)      0.737        251 (26.9)        211 (25.2)                       0.91 (0.74∼1.12)          0.392
                GG      15 (2.5)     16 (3.2)              1.31 (0.64∼2.69)     0.466         25 (2.7)          19 (2.3)                        0.82 (0.45∼1.51)          0.532
               AG+GG   168 (28.0)   147 (29.4)             1.07 (0.82∼1.39)     0.609        276 (29.6)        230 (27.5)                       0.91 (0.73∼1.11)          0.334
  BIRC5         TT     353 (58.8)   277 (55.3)    0.199    1.00 (referent)                    559 (60)          460 (55)           0.008        1.00 (referent)       
  rs2239680     TC     215 (35.8)   185 (36.9)             1.10 (0.86∼1.41)     0.473        331 (35.5)        312 (37.3)                       1.14 (0.94∼1.40)          0.179
                CC      32 (5.3)     39 (7.8)              1.56 (0.95∼2.55)     0.079         42 (4.5)          64 (7.7)                        1.85 (1.23∼2.79)          0.004
               TC+CC   247 (41.2)   224 (44.7)             1.16 (0.91∼1.47)     0.236         373 (40)          376 (45)                        1.22 (1.01∼1.47)          0.035
  FGF2          TT     452 (75.3)   401 (79.9)    0.166    1.00 (referent)                   729 (78.2)        660 (78.6)          0.018        1.00 (referent)       
  rs1476215     TA     134 (22.3)   89 (17.7)              0.75 (0.55∼1.01)     0.059        184 (19.7)        145 (17.3)                       0.98 (0.78∼1.23)          0.26
                AA      14 (2.3)     12 (2.4)              0.97 (0.44∼2.12)     0.933          19 (2)           35 (4.2)                        0.87 (0.68∼1.11)          0.012
               TA+AA   148 (24.7)   101 (20.1)             0.77 (0.57∼1.03)     0.071        203 (21.8)        180 (21.4)                       2.03 (1.15∼3.58)          0.858
  E2F1          GG     325 (54.2)   277 (55.2)    0.869    1.00 (referent)                    503 (54)         431 (51.3)          0.104        1.00 (referent)       
  rs3213180     GC     224 (37.3)   180 (35.9)             0.95 (0.73∼1.22)     0.650        352 (37.8)        315 (37.5)                       1.04 (0.85∼1.27)          0.669
                CC      51 (8.5)     45 (9.0)              1.03 (0.68∼1.59)     0.872         77 (8.3)          94 (11.2)                       1.42 (1.02∼1.97)          0.032
               GC+CC   275 (45.8)   225 (44.8)             0.96(0.76∼1.21)      0.735         429 (46)         409 (48.7)                       1.11 (0.92∼1.34)          0.264
  IL16          TT     243 (40.5)   156 (31.1)    0.002    1.00 (referent)                   369 (39.5)        256 (30.5)         0.00004       1.00 (referent)       
  rs1131445     TC     284 (47.3)   258 (51.4)             1.42 (1.09∼1.85)     0.008        453 (48.5)        438 (52.1)                   **1.40 (1.14**∼**1.72)**   **0.0014**
                CC     73 (12.2)    88 (17.5)              1.88 (1.31∼2.73)    0.0006         112 (12)         146 (17.4)                   **1.88 (1.4**∼**2.52)**    **0.00002**
               TC+CC   357 (59.5)   346 (68.9)             1.51(1.18∼1.93)    **0.001**      565 (60.5)        584 (69.5)                   **1.49 (1.22**∼**1.81)**   **0.00007**

*P* value was calculated using a χ^2^ test with 2 d.f.

Adjusted for age, smoking status, education level, age at primiparity, marital status, and HPV infection status. Bold characters indicate the corresponding *P* values, and the ORs were statistically significant after considering FPRP.

Abbreviations: CI, confidence interval; OR, odds ratio.

3 Serum IL-16 level and its correlation with the *IL-16* rs1131445 genotype {#s3c}
---------------------------------------------------------------------------

Given the observed notable association between the rs1131445 and cervical cancer risk, we further investigate the serum IL-16 levels in controls and patients with cervical cancer as well as the potential regulatory effects of the rs1131445 genotype on serum IL-16. We selected 100 patients with cervical cancer and 80 controls from the subjects of Study 2 and examined their serum IL-16 levels by ELISA. The serum IL-16 of patients with cervical cancer significantly increased compared to controls (*P* = 0.001, [Figure 1A](#pone-0086061-g001){ref-type="fig"}). Moreover, in patients with cervical cancer, there was a marked correlation between the serum IL-16 and rs1131445 genotype (*P* = 0.001). The rs1131445 C allele-carrying patients had a higher serum IL-16 than the non-carriers (*P*\<0.05, [Figure 1B](#pone-0086061-g001){ref-type="fig"}). Furthermore, we did not note any statistically significant association of serum IL-16 with the clinical stage and histological type of the cervical cancer (data not shown).

![Elevated serum IL-16 levels in patients with cervical cancer and their correlation with the rs1131445 genotype.\
A. Serum IL-16 levels in controls and patients with cervical cancer, as measured by ELISA. B. Correlations of serum IL-16 levels with genotype in controls and patients. Data were expressed as the mean ± SEM. \**P*\<0.05 vs. controls group. + *P*\<0.05 vs. patients with TT genotype.](pone.0086061.g001){#pone-0086061-g001}

4 The effect of rs1131445 on the interaction between miR-135b and *IL-16* 3′-UTR {#s3d}
--------------------------------------------------------------------------------

A putative binding site within the 3′-UTR of *IL-16* for miR-135b has been identified using miRBase, miRanda, and PicTar software. It was also predicted that the substitution from the T to the C allele in rs1131445 could decrease the Gibbs binding free energy of miRNA-mRNA by 3.93 KJ/mol [@pone.0086061-Landi1], which suggests that this SNP could affect the *IL-16* gene expression by altering the miRNA-mRNA binding affinity ([Figure 2A](#pone-0086061-g002){ref-type="fig"}). To test this hypothesis, a luciferase assay was performed in the HeLa and SiHa cervical cancer cell lines, which transfected with the pGL3-C-allele or pGL3-T-allele constructs accompanied by chemically synthesized miRNAs miR-135b or a negative control miRNA ([Figure 2A](#pone-0086061-g002){ref-type="fig"}). For both constructs, in the presence of miR-135b mimics, the expression of luciferase was significantly reduced ([Figure 2B-C](#pone-0086061-g002){ref-type="fig"}), which confirms the functional potential of the miRNA-mRNA interaction. In contrast, the negative control miRNA with no predicting binding site in the *IL-16* 3′-UTR has no effect on the luciferase expression ([Figure 2B--C](#pone-0086061-g002){ref-type="fig"}). Moreover, we found that the C allele resulted in a modest but statistically significant increase of luciferase expression compared to that of the T allele ([Figure 2B--C](#pone-0086061-g002){ref-type="fig"}).

![The effect of SNP rs1131445 on the interaction between the *IL-16* 3′-UTR and miR-135b.\
A. Schema of *IL-16* 3′-UTR harboring a putative miR-135b binding site, the position of rs1131445, and the construct of pGL3-IL-16-3′-UTR-T/C. B and C. Relative luciferase activity in the presence of miR-135b or the negative control miRNA is shown for the *IL-16* 3′-UTR with the T allele and C allele in the HeLa (B) and SiHa (C) cancer cells; data are shown as the percentage relative to the luciferase activity of the cells transfected with the NC and T allele; the error bar represents s.e. from three independent experiments; \**P*\<0.05, \*\**P*\<0.05, \*\*\**P*\<0.01. NC represents the negative control.](pone.0086061.g002){#pone-0086061-g002}

Discussion {#s4}
==========

In the present study, we screened out a cervical cancer susceptibility variant from the miRNA-binding site SNPs within 37 cancer-related genes by a two-stage study. We found that the SNP rs1131445 C allele in the 3′-UTR of *IL-16* was associated with an increased risk of cervical cancer. Using a luciferase assay, we found that miRNA-135b markedly decreased the luciferase expression of pGL3-IL-16-3′-UTR constructs in the Hela and SiHa cervical cancer cell lines. More importantly, these inhibitory effects of miRNA-135b were weakened by the substitution from the T to the C allele in rs1131445. These results support the hypothesis that the variations in the putative miRNA target sites could constitute a susceptibility factor for cervical cancers.

IL-16 is synthesized by various immune and parenchymal cells, including CD4 and CD8 T cells, eosinophils, macrophage/dendritic cells, mast cells, bronchial epithelium, and fibroblasts [@pone.0086061-Cruikshank1]. The protein directly translated from *IL-16* mRNA is a precursor molecule and must be cleaved into two fragments by caspase-3. The cleaved bioactive IL-16 is released following stimulation by histamine or serotonin and acts as a chemoattractant factor to regulate the inflammatory response [@pone.0086061-Cruikshank1]. Recently, IL-16 has been recognized as an important promoting factor for tumors [@pone.0086061-Kovacs1], [@pone.0086061-Liebrich1], [@pone.0086061-Milke1], [@pone.0086061-Comperat1]. The production of IL-16 correlates with the onset and progression of various hematopoietic cancers and solid cancers [@pone.0086061-Kovacs1]. The constitutive IL-16 expression has also been found to upregulate in gliomas [@pone.0086061-Liebrich1] and prostate cancer [@pone.0086061-Comperat1]. Moreover, its expression in prostate cancer tissue was correlated to tumor aggressiveness and biochemical relapse of the disease [@pone.0086061-Comperat1]. Serum IL-16 level elevation has been observed in multiple cancers [@pone.0086061-Carlsson1], [@pone.0086061-Yellapa1]. Serum IL-16 is a predictor for the development of distant metastases of breast cancer [@pone.0086061-Carlsson1]. Moreover, in breast cancer, the upregulation of secreted IL-16 enhances the infiltration of monocytes into the tumor tissue [@pone.0086061-Milke1].

The roles of IL-16 in cervical cancer pathophysiology remain largely unclear. Our findings of serum IL-16 elevation following cervical carcinogenesis and the notable association of *IL-16* with cervical cancer risk suggest that IL-16 could regulate cervical carcinogenesis. This hypothesis is supported by the carcinogenic effects of persistent inflammation on cervix uteri. Immune cell infiltration into tumors is a critical determinant for cervical carcinogenesis [@pone.0086061-Milke1], [@pone.0086061-Boccardo1]. The macrophage infiltrating in cervix uteri increases linearly with cervical disease progression, from normal cervix, low-grade to high grade squamous intraepithelial lesions, to invasive cancer [@pone.0086061-Hammes1]. Tumor-associated macrophages contribute to tumor progression by exerting their multiple functions in tumor cell proliferation, tumor cell invasion, and tumor angiogenesis [@pone.0086061-Fukuda1]. Besides macrophages, CD4^+^ regulatory T cells can contribute to carcinogenesis by curtailing the efficacy of T cell immune responses against cancers [@pone.0086061-Hiura1]. In cervical cancer, HPV-specific CD4^+^ T cells suppress cytokine (IFN-γ, IL-2) production to interfere with the anti-tumor immune response [@pone.0086061-vanderBurg1]. IL-16 can be expressed by epithelial cells under inflammatory conditions [@pone.0086061-Bellini1] and serves to chemoattract monocyptes/macrophages and CD4^+^ T cells to the infection site [@pone.0086061-Cruikshank2]. Moreover, secreted IL-16 stimulates monocyptes/macrophages to produce various pro-inflammatory cytokines [@pone.0086061-Mathy1]. Therefore, it is plausible that the upregulation of IL-16 in HPV-induced inflammation could promote carcinogenesis by the hyperfunction of macrophages, HPV-specific CD4^+^ T cells, or other inflammatory cells.

Here, we provide the first evidence that rs1131445 in the miR-135b binding site of *IL-16* 3′-UTR, which can affect IL-16 protein expression by interfering with miR135b suppressive function, was significantly associated with the risk of cervical cancer. A functional assay in vitro indicated that the transfection of HeLa and SiHa cells carrying the *IL-16* 3′-UTR with miR-135b mimic significantly reduces the expression of luciferase, which suggests that IL-16 might be targeted by miR-135b. The rs1131445 T to C change inhibits the interaction of miR-135b with *IL-16* 3′-UTR and upregulates its expression. Consistent with this speculation, in vivo analysis revealed that patients who carry the rs1131445 C allele had a higher serum IL-16 than non-carriers, which led to an elevated serum IL-16 of patients compared to healthy controls. The upregulation of miR-135b has been found in cervical cancer [@pone.0086061-AGardiner1], which could inhibit the expression of *IL-16* by targeting its 3′-UTR. The rs1131445 C allele impairs the binding of miR-135b to the target and leads to higher constitutive expression of *IL-16* and subsequent release to serum. Given the important regulatory roles of IL-16 release in the immune response and the consequent level of the local inflammatory microenvironment, individuals who carry the rs3134615 C allele would be expected to have elevated risk for cervical cancer. In conclusion, our data suggested that rs1131445, as a functional variant, could modulate the individual risk of cervical cancer likely by deregulating the post-transcriptional regulation of miRNA-135b on *IL-16* expression. Although our study used reasonable numbers of patients and controls and rigorous statistical methods, we could not completely rule out the possibility that spurious results emerged from our case-control association study design due to chance or population stratification. Therefore, further large scale replication study using different ethnic populations, or family-based analysis, or prospective cohort design is required to produce very conclusive results. Additional functional analyses are also required to clarify the exact roles of IL-16 in cervical cancer genesis and progression in the future.
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